Design of VICTORION-2 Prevent: A randomized double-blind, placebo-controlled trial, assessing the impact of inclisiran on major adverse cardiovascular events in patients with established cardiovascular disease.
- DOI
- 10.1016/j.ahj.2026.107493
- Published
- 2026-05-26
- Container
- Am Heart J
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ahj.2026.107493,
title = {Design of VICTORION-2 Prevent: A randomized double-blind, placebo-controlled trial, assessing the impact of inclisiran on major adverse cardiovascular events in patients with established cardiovascular disease.},
author = {Steg PG and Goodman SG and Jukema JW and Martens P and Zirlik A and Bhatt DL and Menon V and Szarek M and Lesogor A and Stratz C and O'Donoghue F and Mena-Madrazo J and Shao Q and Liu K and Mehran R and VICTORION-2 Prevent Investigators.},
year = {2026},
journal = {Am Heart J},
doi = {10.1016/j.ahj.2026.107493},
url = {https://doi.org/10.1016/j.ahj.2026.107493}
}RIS
TY - JOUR TI - Design of VICTORION-2 Prevent: A randomized double-blind, placebo-controlled trial, assessing the impact of inclisiran on major adverse cardiovascular events in patients with established cardiovascular disease. AU - Steg PG AU - Goodman SG AU - Jukema JW AU - Martens P AU - Zirlik A AU - Bhatt DL AU - Menon V AU - Szarek M AU - Lesogor A AU - Stratz C AU - O'Donoghue F AU - Mena-Madrazo J AU - Shao Q AU - Liu K AU - Mehran R AU - VICTORION-2 Prevent Investigators. PY - 2026 JO - Am Heart J DO - 10.1016/j.ahj.2026.107493 UR - https://doi.org/10.1016/j.ahj.2026.107493 ER -
APA
PG, S., SG, G., JW, J., P, M., A, Z., DL, B., V, M., M, S., A, L., C, S., F, O., J, M., Q, S., K, L., R, M., & Investigators., V. P. (2026). Design of VICTORION-2 Prevent: A randomized double-blind, placebo-controlled trial, assessing the impact of inclisiran on major adverse cardiovascular events in patients with established cardiovascular disease.. Am Heart J. https://doi.org/10.1016/j.ahj.2026.107493
Source records
- europe-pmc · retrieved 2026-09-25T22:29:32.851Z